You are here

Article Text

Article menu
Download PDFPDF
Poster Presentations
Vasculitis
FRI0270 Tocilizumab Compared to Anti-TNFα Agents in Refractory Aortitis
  1. N. Palmou-Fontana1,
  2. J. Loricera1,
  3. R. Blanco1,
  4. J.L. Hernández1,
  5. S. Castañeda2,
  6. N. Ortego3,
  7. E. Peirό1,
  8. P. Collado4,
  9. S. Melchor5,
  10. A. Mera6,
  11. E. Pérez-Pampín6,
  12. E. Rubio7,
  13. J. Calvo-Alén8,
  14. E. Aurrecoechea9,
  15. Í. Rúa-Figueroa10,
  16. M. Mínguez11,
  17. G. Herrero-Beaumont12,
  18. B. Bravo13,
  19. J. Rosas14,
  20. J. Narváez15,
  21. J. Calvo-Catalá16,
  22. R. Ariza17,
  23. M. Freire18,
  24. P. Lluch19,
  25. C. Mata20,
  26. E. Galíndez-Aguirregoikoa21,
  27. J.M. Blanco-Madrigal21,
  28. A. Sánchez-Andrade22,
  29. J. Salvatierra23,
  30. V. Calvo-Río1,
  31. C. González-Vela1,
  32. T. Pina1,
  33. M.A. González-Gay1
  1. 1Marqués De Valdecilla, IDIVAL, Santander
  2. 2La Princesa, Madrid
  3. 3San Cecilio, Granada
  4. 4Severo Ochoa
  5. 512 de Octubre, Madrid
  6. 6Complejo Hospitalario de Santiago, Santiago de Compostela
  7. 7V. del Rocío, Sevilla
  8. 8Sierrallana
  9. 9Sierrallana, Torrelavega
  10. 10Dr. Negrín, Las Palmas
  11. 11San Juan, Alicante
  12. 12Fundaciόn Jiménez Díaz, Madrid
  13. 13V. de las Nieves, Granada
  14. 14M. Baixa, Villajoyosa
  15. 15Bellvitge, Barcelona
  16. 16General de Valencia, Valencia
  17. 17V. Macarena, Sevilla
  18. 18Complexo Hospitalario A Coruña, A Coruña
  19. 19Mateu Orfila, Menorca
  20. 20Laredo, Laredo
  21. 21Basurto, Vizcaya
  22. 22L. Augusti, Lugo
  23. 23San Cecilio, Granada, Spain

Abstract

Background Aortitis is often refractory to conventional immunosuppressive (IS) therapy. The use of biological therapy, such as tocilizumab (TCZ) and anti-TNFα agents, had been reported.

Objectives Our aim was to compare the efficacy of TCZ with anti-TNFα therapy in patients with aortitis.

Methods Retrospective multicenter study of patients with aortitis refractory to traditional IS agents.

Results We studied 44 patients (36 W/8 M; 51±19 years); 25 with TCZ and 19 with anti-TNFα agents (IFX=14, ADA=3, and ETN=2). Baseline features of patients on TCZ compared to the antiTNFα group (always in this order) showed a) mean age: 58±20 vs 42±13 years (p=0.003), b) women: 84% vs 79%, (p=0.97), c) underlying conditions: Takayasu arteritis, 8 vs 11 cases (p=0.08); giant cell arteritis, 15 vs 2 (p=0.0025); relapsing polychondritis, 1 vs 1 (p=0.59); ulcerative colitis, 0 vs 1 (p=0.88); Crohn's disease, 0 vs 1 (p=0.88); Behçet's disease, 0 vs 1 (p=0.88); sarcoidosis, 0 vs 1 (p=0.88); psoriatic arthritis, 0 vs 1 (p=0.88); and idiopathic aortitis, 1 vs 0 (p=0.88) d) mean of previous traditional IS agents (1.1 vs 1.7, p=0.069) and biological therapies (0.3 vs 0.1, p=0.23). After 3 months of treatment, most patients in both groups had experienced a clinical and acute phase reactants improvement, as well as a reduction of the corticosteroid dose. This favorable response was maintained over time (Table). The improvement observed by imaging techniques was similar in both groups. After a median follow-up of 12 [9-17] vs 16 [12-36] months (p=0.014), TCZ was withdrawn due to severe neutropenia (n=1); recurrent pneumonia (n=1); cytomegalovirus infection (n=1) and systemic lupus erythematosus (n=1). Other adverse effects were thrombocytopenia (n=1) and infusional hypotension (n=1). One patient died due to a stroke in the setting of an infective endocarditis, and another one discontinued TCZ because of inefficacy. In the anti-TNFα group, 3 patients on IFX discontinued due to inefficacy (n=1), recurrent pneumonia (n=1) and severe infusional reaction (n=1).

Figure

Conclusions Biological therapy appears effective and relatively safe in patients with aortitis refractory to traditional IS drugs. In this series, TCZ seems to be slightly more effective than antiTNFα agents.

Disclosure of Interest None declared

https://doi.org/10.1136/annrheumdis-2015-eular.3849

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.